this must be archive.php

MONOCLE

Written by

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

MONOCLE IS NOW CLOSED TO RECRUITMENT

The trial was unable to demonstrate that Tefinostat had any effect in modifying CMML

    1. SUBTYPE OF MDS: Chronic myelomonocytc leukaemia (CMML)
    2. SEVERITY OF MDS: CMML specific prognostic score (CPSS) Intermediate-2 or high risk
    3. NAME OF DRUG: Tefinostat, a histone deacetylase inhibitor that targets monocytes. Tefinostat will be administered orally on a continuous basis for at least 6 cycles each 28 days in length.

Read More

MEDALIST (HAEM 5606)

Written by

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

MEDALIST IS NOW CLOSED TO RECRUITMENT

Treatment with Luspatercept resulted in a significantly reduced transfusion burden compared with placebo. Regulatory submissions planned in the United States and Europe in the first half of 2019.

    1. SUB-TYPE OF MDS: IPSS-R and ring sideroblasts
    2. SEVERITY OF MDS: Low or Intermediate
    3. NAME OF DRUG: Luspatercept, a protein found to promote red blood cell formation by regulating the growth of red blood cells during the late-stage of their development. It works differently to erythropoietin.

Read More

Free donations by shopping